Third-generation antidepressants: do they offer advantages over the SSRIs? (Q28209534)

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

Europe PubMed Central

title

Third-generation antidepressants: do they offer advantages over the SSRIs? (English)

0 references

author name string

J S Olver

series ordinal

1

0 references

G D Burrows

series ordinal

2

0 references

T R Norman

series ordinal

3

0 references

language of work or name

English

0 references

publication date

2001

0 references

published in

CNS Drugs

0 references

volume

15

0 references

issue

12

0 references

page(s)

941-54

0 references

cites work

1 reference

12 December 2020

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

12 December 2020

Drug interactions with newer antidepressants: role of human cytochromes P450

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

12 December 2020

Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).

1 reference

12 December 2020

Binding of antidepressants to human brain receptors: focus on newer generation compounds

1 reference

12 December 2020

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia

1 reference

12 December 2020

A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients

1 reference

12 December 2020

Pharmacokinetic interactions of antidepressants

1 reference

12 December 2020

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

12 December 2020

A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression

1 reference

12 December 2020

Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia

1 reference

12 December 2020

Toxicities and outcomes associated with nefazodone poisoning: an analysis of 1,338 exposures

1 reference

12 December 2020

A comparison of venlafaxine, trazodone, and placebo in major depression.

1 reference

12 December 2020

Nefazodone-induced liver failure: report of three cases

1 reference

12 December 2020

Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.

1 reference

12 December 2020

Safety of mirtazapine in overdose

1 reference

12 December 2020

Antidepressant drug therapy: the role of the new antidepressants

1 reference

12 December 2020

Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

First report of mirtazapine overdose.

1 reference

12 December 2020

Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates

1 reference

12 December 2020

A study involving venlafaxine overdoses: comparison of fatal and therapeutic concentrations in postmortem specimens

1 reference

12 December 2020

Serotonin syndrome due to venlafaxine overdose

1 reference

12 December 2020

Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression

1 reference

12 December 2020

Cardiovascular safety in depressed patients: focus on venlafaxine

1 reference

12 December 2020

Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients

1 reference

12 December 2020

Antidepressants: can we determine how quickly they work? Issues from the literature.

1 reference

12 December 2020

Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.

1 reference

12 December 2020

Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression.

1 reference

12 December 2020

Mirtazapine versus selective serotonin reuptake inhibitors

1 reference

12 December 2020

Long-term treatment of depression with nefazodone

1 reference

12 December 2020

Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4

1 reference

12 December 2020

Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

1 reference

12 December 2020

Tolerability and safety: essentials in antidepressant pharmacotherapy

1 reference

12 December 2020

Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.

1 reference

12 December 2020

Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder

1 reference

12 December 2020

A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression

1 reference

12 December 2020

A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression

1 reference

12 December 2020

Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction

1 reference

12 December 2020

A New Depression Scale Designed to be Sensitive to Change

1 reference

12 December 2020

How fast are antidepressants?

1 reference

12 December 2020

Nefazodone in the treatment of severe, melancholic, and recurrent depression

1 reference

12 December 2020

Reboxetine versus fluoxetine: an overview of efficacy and tolerability.

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Fatal venlafaxine overdose.

1 reference

12 December 2020

Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes

1 reference

12 December 2020

Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression

1 reference

12 December 2020

Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

12 December 2020

Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine

1 reference

12 December 2020

Venlafaxine. A review of its pharmacology and therapeutic potential in depression

1 reference

12 December 2020

Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial

1 reference

12 December 2020

Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, org 3770 and its enantiomers

1 reference

12 December 2020

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam

1 reference

12 December 2020

A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression

1 reference

12 December 2020

Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.

1 reference

12 December 2020

Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam

1 reference

12 December 2020

Reboxetine: a review of antidepressant tolerability.

1 reference

12 December 2020

Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder

1 reference

12 December 2020

Cardiovascular and neurological toxicity of venlafaxine

1 reference

12 December 2020

A double-blind comparison of nefazodone, imipramine, and placebo in major depression

1 reference

12 December 2020

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

1 reference

12 December 2020

The impact of antidepressant use on social functioning: reboxetine versus fluoxetine

1 reference

12 December 2020

Drug-drug interactions involving antidepressants: focus on venlafaxine

1 reference

12 December 2020

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

1 reference

12 December 2020

Antidepressant drugs: disturbing and potentially dangerous adverse effects

1 reference

12 December 2020

Update in the pharmacotherapy of depression

1 reference

12 December 2020

Nefazodone and imipramine in major depression: a placebo-controlled trial

1 reference

12 December 2020

A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression

1 reference

12 December 2020

Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study

1 reference

12 December 2020

A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression

1 reference

12 December 2020